Monitoring of Risedronate by biochemical bone markers in clinical practice.
The study of trend of Risedronate 10 mg/day in menopausal women with a high level of resorptive bone marker (Betacrosslaps, CTx) by the following bone markers:Bone alkaline phosphatase (formation marker) total alkaline phosphatase (TAlP), NMID osteocalcin, undercarboxylated osteocalcin (UcOC) and procollagen type 1 carboxyl propeptides (PICP). Risedronate does not suppress bone resorption deeply that enhances the bone recovers quickly after withdrawal. The level of undercarboxylated osteocalcin was increased after one year of treatment; it may be a sign of vitamin K2 deficiency. The bone alkaline phosphatase was decreased at the end of 12 months and Procollagen type 1 carboxyl propeptides (PICP) of twelfth month changed significantly compared to the sixth months of treatment (p=0.001) The once week 70 mg/week group also changed of CTx the same as daily dose group.